Pardes Biosciences to Host Virtual Investor Event
09 févr. 2022 07h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...
Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022
08 févr. 2022 07h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...
Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections
03 févr. 2022 07h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...
Pardes Biosciences to Present at J.P. Morgan Healthcare Conference
05 janv. 2022 07h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...
Pardes Biosciences Debuts as a Publicly Traded Company Focused on Oral Antiviral Therapies to Potentially Treat and Prevent COVID-19
27 déc. 2021 07h00 HE
|
Pardes Biosciences, Inc
Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 Gross proceeds made available to Pardes Biosciences from transaction totaled approximately $274 million,...
Pardes Biosciences Appoints New Chief Business and Strategy Officer
30 nov. 2021 07h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to...
Pardes Bioscience Announces Issuance of Its First U.S. Patent
21 sept. 2021 16h05 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical--stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office has issued a new...
Pardes Biosciences Initiates First-in-Human Trial for PBI-0451, an Oral Antiviral in Development to Treat and Prevent SARS-CoV-2 Infections
26 août 2021 08h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the...
Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors
05 août 2021 07h00 HE
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat...